Idera Pharmaceuticals Inc  

(Public, NASDAQ:IDRA)   Watch this stock  
Find more results for IDRA
2.94
+0.28 (10.52%)
After Hours: 2.95 +0.01 (0.34%)
Apr 16, 7:15PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.61 - 3.03
52 week 0.49 - 6.87
Open 2.80
Vol / Avg. 2.98M/4.34M
Mkt cap 242.14M
P/E     -
Div/yield     -
EPS -0.51
Shares 82.36M
Beta 2.20
Inst. own 30%
Mar 13, 2014
Q4 2013 Idera Pharmaceuticals, Inc. Earnings Conference Call - Webcast
Mar 5, 2014
Idera Pharmaceuticals, Inc. at Cowen Health Care Conference - Webcast
Feb 25, 2014
Idera Pharmaceuticals, Inc. at RBC Capital Markets Healthcare Conference - Webcast
Feb 11, 2014
Idera Pharmaceuticals, Inc. at Biotechnology Industry Organization CEO & Investor Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -152250.00% -38778.72%
Operating margin -151800.00% -38657.45%
EBITD margin - -38365.96%
Return on average assets -63.91% -76.44%
Return on average equity -107.39% -228.45%
Employees 18 -
CDP Score - -

Address

167 Sidney Street
CAMBRIDGE, MA 02139
United States - Map
+1-617-6795500 (Phone)
+1-617-6795592 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. During the year ended December 31, 2011, the Company collaborated with Merck Sharp & Dohme Corp., for the use of agonists of TLRs 7, 8, and 9 as vaccine adjuvants for cancer, infectious diseases, and Alzheimer�s disease. In November 2011, the Company reacquired rights to IMO-2055 from Merck KGaA, Darmstadt, Germany, its former collaborator.

Officers and directors

James A. Geraghty Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Sudhir Agrawal President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Youssef El Zein Independent Vice Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Louis J. Arcudi III Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
Age: 52
Bio & Compensation  - Reuters
Louis Brenner M.D. Senior Vice President, Chief Medical Officer
Age: 43
Bio & Compensation  - Reuters
Robert D. Arbeit M.D. Vice President - Clinical Development
Age: 65
Bio & Compensation  - Reuters
Timothy M. Sullivan Ph.D. Vice President - Development Programs and Alliance Management
Age: 58
Bio & Compensation  - Reuters
William S. Reardon CPA Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
Julian C. Baker Director
Age: 48
Bio & Compensation  - Reuters
Mark A. Goldberg M.D. Director
Age: 54
Bio & Compensation  - Reuters